Gold prices briefly hit record high over $3,500/oz on fiscal, tariff concerns
Patricia C. Hirano, Senior Vice President of Regulatory Affairs at Soleno Therapeutics Inc. (NASDAQ:SLNO), executed a sale of 3,782 shares of the company’s common stock on April 1, 2025. The transaction occurred with the stock trading near its 52-week high of $73.97, following a remarkable 52% gain year-to-date. The shares were sold at an average price of $70.11, amounting to a total transaction value of $265,156.
Following this transaction, Hirano retains ownership of 27,036 shares, which includes certain restricted stock units (RSUs) subject to vesting schedules and conditions. The sale was conducted under a Rule 10b5-1 trading plan, which Hirano had adopted on September 13, 2024. According to InvestingPro data, analyst price targets for SLNO range from $81 to $123, suggesting potential upside from current levels. Discover more valuable insights and 15+ additional ProTips with an InvestingPro subscription.
In other recent news, Soleno Therapeutics Inc. has made significant strides with the approval of its drug VYKAT XR by the U.S. Food and Drug Administration (FDA). This approval is for the treatment of hyperphagia in patients with Prader-Willi Syndrome (PWS), a genetic disorder causing severe hunger. H.C. Wainwright raised its price target for Soleno to $100, citing the FDA’s approval as a key factor, while maintaining a Buy rating. Similarly, Stifel increased its price target to $108, also maintaining a Buy rating and noting the drug’s potential market opportunity.
Piper Sandler reiterated an Overweight rating with a $93 target, emphasizing the drug’s favorable labeling and anticipated strong market adoption. Guggenheim also raised its target to $81, maintaining a Buy rating and projecting significant revenue from the drug by 2030. Analysts from these firms are optimistic about the drug’s impact on Soleno’s financial performance, with some projecting revenues reaching billions of dollars. The approval of VYKAT XR marks a milestone for Soleno Therapeutics, with analysts expressing confidence in the company’s commercial strategy and future growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.